Regarding CLL, analyses of ibrutinib-mediated effects on NK cell proliferation and functions are limited: Kohrt and colleagues showed that ibrutinib inhibits NK cell proliferation, TNF-α production and lead to an anti-CD20-mediated ADCC impairment against chronic lymphocytic leukemia blasts mediated by rituximab [142]. Here, TNF is linked to B-cell chronic lymphocytic leukemia.